Abstract
Abstract
Objectives
This study aims to explore the diagnostic and prognostic value of lncRNA PTOV1-AS1 in patients with breast cancer (BC).
Methods
This study included 104 BC patients as case group and 86 healthy volunteers as control group. Serum PTOV1-AS1 expression was detected in all subjects by RT-qPCR, and receiver operating characteristic (ROC) curves were plotted to assess the clinical diagnostic value of PTOV1-AS1 for BC. Serum PTOV1-AS1 expression under different clinicopathological characteristics in BC patients was detected by RT-qPCR. The prognostic performance of PTOV1-AS1 in BC was assessed using the Kaplan–Meier method and Cox regression analysis.
Results
Serum PTOV1-AS1 expression in BC patients was remarkably higher than that in healthy controls. The area under the ROC curve (AUC) was 0.954, the sensitivity was 81.70 %, and the specificity was 97.67 %, which demonstrated that PTOV1-AS1 could distinguish BC patients from healthy volunteers. RT-qPCR results indicated significant differences in the expression of PTOV1-AS1 among differentiation, tumor nodes metastasis (TNM) stage and lymph node metastasis (LNM). Additionally, patients with low PTOV1-AS1 expression had better progression-free survival (PFS) than those with high expression, and PTOV1-AS1 was an independent prognostic biomarker for BC.
Conclusions
PTOV1-AS1 expression is upregulated in the serum of BC patients and is closely linked to poor prognosis. It provides a new perspective and theoretical basis for the diagnosis and prognostic assessment of BC, and is a potential biomarker.